<?xml version="1.0" encoding="utf-8"?>
<feed xmlns="http://www.w3.org/2005/Atom">
    <id>https://macwaneric.github.io/cancer.rss.feed/index.html</id>
    <title>CancerFeed</title>
    <updated>2023-11-05T00:54:11.836Z</updated>
    <generator>osmosfeed 1.15.1</generator>
    <link rel="alternate" href="https://macwaneric.github.io/cancer.rss.feed/index.html"/>
    <link rel="self" href="https://macwaneric.github.io/cancer.rss.feed/feed.atom"/>
    <entry>
        <title type="html"><![CDATA[SRCAP Mutations and Cellular Stressors Promote Clonal Hematopoiesis]]></title>
        <id>pubmed:37921439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37921439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[SRCAP mutations promote clonal expansion of hematopoietic stem cells (HSC) in response to cellular stress.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP Mutations and Cellular Stressors Promote Clonal Hematopoiesis]]></title>
        <id>pubmed:37921439</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37921439/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[SRCAP mutations promote clonal expansion of hematopoietic stem cells (HSC) in response to cellular stress.]]></summary>
        <author>
            <name>Clonal Hematopoiesis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalised neoantigen-based therapy in colorectal cancer]]></title>
        <id>pubmed:37921274</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37921274/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) has become one of the most common tumours with high morbidity, mortality and distinctive evolution mechanism. The neoantigens arising from the somatic mutations have become considerable treatment targets in the management of CRC. As cancer-specific aberrant peptides, neoantigens can trigger the robust host immune response and exert anti-tumour effects while minimising the emergence of adverse events commonly associated with alternative therapeutic regimens. In this...]]></summary>
        <author>
            <name>Ya-Juan Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Personalised neoantigen-based therapy in colorectal cancer]]></title>
        <id>pubmed:37921274</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37921274/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Colorectal cancer (CRC) has become one of the most common tumours with high morbidity, mortality and distinctive evolution mechanism. The neoantigens arising from the somatic mutations have become considerable treatment targets in the management of CRC. As cancer-specific aberrant peptides, neoantigens can trigger the robust host immune response and exert anti-tumour effects while minimising the emergence of adverse events commonly associated with alternative therapeutic regimens. In this...]]></summary>
        <author>
            <name>Ya-Juan Zhu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?]]></title>
        <id>pubmed:37915324</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37915324/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this article, we reviewed the possible mechanisms linking the clonal hematopoiesis of indeterminate potential (CHIP) to chronic myeloproliferative neoplasms (MPNs), autoimmune diseases (ADs), and cardiovascular diseases (CADs). CHIP is characterized by the presence of clonal mutations with an allelic frequency >2% in the peripheral blood without dysplasia, overt hematological neoplasms, or abnormalities in blood cell count. The prevalence may reach 20% of elderly healthy individuals and is...]]></summary>
        <author>
            <name>Giovanni Fulvio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?]]></title>
        <id>pubmed:37915324</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37915324/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this article, we reviewed the possible mechanisms linking the clonal hematopoiesis of indeterminate potential (CHIP) to chronic myeloproliferative neoplasms (MPNs), autoimmune diseases (ADs), and cardiovascular diseases (CADs). CHIP is characterized by the presence of clonal mutations with an allelic frequency >2% in the peripheral blood without dysplasia, overt hematological neoplasms, or abnormalities in blood cell count. The prevalence may reach 20% of elderly healthy individuals and is...]]></summary>
        <author>
            <name>Giovanni Fulvio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Philadelphia chromosome-negative myeloproliferative chronic neoplasms: is clonal hematopoiesis the main determinant of autoimmune and cardio-vascular manifestations?]]></title>
        <id>pubmed:37915324</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37915324/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In this article, we reviewed the possible mechanisms linking the clonal hematopoiesis of indeterminate potential (CHIP) to chronic myeloproliferative neoplasms (MPNs), autoimmune diseases (ADs), and cardiovascular diseases (CADs). CHIP is characterized by the presence of clonal mutations with an allelic frequency >2% in the peripheral blood without dysplasia, overt hematological neoplasms, or abnormalities in blood cell count. The prevalence may reach 20% of elderly healthy individuals and is...]]></summary>
        <author>
            <name>Giovanni Fulvio</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT]]></title>
        <id>pubmed:37913908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37913908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains a key treatment option for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of patients relapse after allo-HSCT, of which 2-5% are donor-derived malignancies (DDM). DDM can arise from a germline genetic predisposition allele or clonal hematopoiesis (CH) in the donor. Increasingly, genetic testing reveals that patient and donor genetic factors contribute to the development of DDM and other allo-HSCT...]]></summary>
        <author>
            <name>Lacey S Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic TET2 Mutations are Associated with Giant Cell Arteritis]]></title>
        <id>pubmed:37909388</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37909388/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH increases risk for development of GCA in a genotype-specific fashion, with greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future. This article is protected by copyright. All rights reserved.]]></summary>
        <author>
            <name>Michelle L Robinette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT]]></title>
        <id>pubmed:37913908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37913908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains a key treatment option for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of patients relapse after allo-HSCT, of which 2-5% are donor-derived malignancies (DDM). DDM can arise from a germline genetic predisposition allele or clonal hematopoiesis (CH) in the donor. Increasingly, genetic testing reveals that patient and donor genetic factors contribute to the development of DDM and other allo-HSCT...]]></summary>
        <author>
            <name>Lacey S Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic TET2 Mutations are Associated with Giant Cell Arteritis]]></title>
        <id>pubmed:37909388</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37909388/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH increases risk for development of GCA in a genotype-specific fashion, with greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future. This article is protected by copyright. All rights reserved.]]></summary>
        <author>
            <name>Michelle L Robinette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Donor-derived malignancy and transplant morbidity: Risks of patient and donor genetics in allogeneic hematopoietic stem cell transplant: Donor-derived malignancy and genetic risks in allo-HSCT]]></title>
        <id>pubmed:37913908</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37913908/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Allogeneic hematopoietic stem cell transplant (allo-HSCT) remains a key treatment option for hematologic malignancies (HMs), although it carries significant risks. Up to 30% of patients relapse after allo-HSCT, of which 2-5% are donor-derived malignancies (DDM). DDM can arise from a germline genetic predisposition allele or clonal hematopoiesis (CH) in the donor. Increasingly, genetic testing reveals that patient and donor genetic factors contribute to the development of DDM and other allo-HSCT...]]></summary>
        <author>
            <name>Lacey S Williams</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic TET2 Mutations are Associated with Giant Cell Arteritis]]></title>
        <id>pubmed:37909388</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37909388/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH increases risk for development of GCA in a genotype-specific fashion, with greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future. This article is protected by copyright. All rights reserved.]]></summary>
        <author>
            <name>Michelle L Robinette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic TET2 Mutations are Associated with Giant Cell Arteritis]]></title>
        <id>pubmed:37909388</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37909388/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-11-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH increases risk for development of GCA in a genotype-specific fashion, with greatest risk being conferred by the presence of mutations in TET2. Somatic TET2 mutations likewise increase the risk of GCA-associated vision loss. Integration of somatic genetic testing in GCA diagnostics may be warranted in the future. This article is protected by copyright. All rights reserved.]]></summary>
        <author>
            <name>Michelle L Robinette</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Determinants of mosaic chromosomal alteration fitness]]></title>
        <id>pubmed:37905118</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37905118/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is characterized by the acquisition of a somatic mutation in a hematopoietic stem cell that results in a clonal expansion. These driver mutations can be single nucleotide variants in cancer driver genes or larger structural rearrangements called mosaic chromosomal alterations (mCAs). The factors that influence the variations in mCA fitness and ultimately result in different clonal expansion rates are not well-understood. We used the Passenger-Approximated Clonal...]]></summary>
        <author>
            <name>Yash Pershad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and somatic drivers in inherited hematologic malignancies]]></title>
        <id>pubmed:37904876</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904876/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited hematologic malignancies are linked to a heterogenous group of genes, knowledge of which is rapidly expanding using panel-based next-generation sequencing (NGS) or whole-exome/whole-genome sequencing. Importantly, the penetrance for these syndromes is incomplete, and disease development, progression or transformation has critical clinical implications. With the earlier detection of healthy carriers and sequential monitoring of these patients, clonal hematopoiesis and somatic driver...]]></summary>
        <author>
            <name>Julian Zoller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients]]></title>
        <id>pubmed:37904125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Lung recipients have a higher prevalence of CHIP and a larger variety of genes with CHIP-associated mutations compared with previous reports for the general population. CHIP did not increase the risk of AR, CLAD, or death in lung recipients.]]></summary>
        <author>
            <name>Aparna C Swaminathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Determinants of mosaic chromosomal alteration fitness]]></title>
        <id>pubmed:37905118</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37905118/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is characterized by the acquisition of a somatic mutation in a hematopoietic stem cell that results in a clonal expansion. These driver mutations can be single nucleotide variants in cancer driver genes or larger structural rearrangements called mosaic chromosomal alterations (mCAs). The factors that influence the variations in mCA fitness and ultimately result in different clonal expansion rates are not well-understood. We used the Passenger-Approximated Clonal...]]></summary>
        <author>
            <name>Yash Pershad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and somatic drivers in inherited hematologic malignancies]]></title>
        <id>pubmed:37904876</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904876/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited hematologic malignancies are linked to a heterogenous group of genes, knowledge of which is rapidly expanding using panel-based next-generation sequencing (NGS) or whole-exome/whole-genome sequencing. Importantly, the penetrance for these syndromes is incomplete, and disease development, progression or transformation has critical clinical implications. With the earlier detection of healthy carriers and sequential monitoring of these patients, clonal hematopoiesis and somatic driver...]]></summary>
        <author>
            <name>Julian Zoller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients]]></title>
        <id>pubmed:37904125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Lung recipients have a higher prevalence of CHIP and a larger variety of genes with CHIP-associated mutations compared with previous reports for the general population. CHIP did not increase the risk of AR, CLAD, or death in lung recipients.]]></summary>
        <author>
            <name>Aparna C Swaminathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Determinants of mosaic chromosomal alteration fitness]]></title>
        <id>pubmed:37905118</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37905118/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is characterized by the acquisition of a somatic mutation in a hematopoietic stem cell that results in a clonal expansion. These driver mutations can be single nucleotide variants in cancer driver genes or larger structural rearrangements called mosaic chromosomal alterations (mCAs). The factors that influence the variations in mCA fitness and ultimately result in different clonal expansion rates are not well-understood. We used the Passenger-Approximated Clonal...]]></summary>
        <author>
            <name>Yash Pershad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and somatic drivers in inherited hematologic malignancies]]></title>
        <id>pubmed:37904876</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904876/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited hematologic malignancies are linked to a heterogenous group of genes, knowledge of which is rapidly expanding using panel-based next-generation sequencing (NGS) or whole-exome/whole-genome sequencing. Importantly, the penetrance for these syndromes is incomplete, and disease development, progression or transformation has critical clinical implications. With the earlier detection of healthy carriers and sequential monitoring of these patients, clonal hematopoiesis and somatic driver...]]></summary>
        <author>
            <name>Julian Zoller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients]]></title>
        <id>pubmed:37904125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Lung recipients have a higher prevalence of CHIP and a larger variety of genes with CHIP-associated mutations compared with previous reports for the general population. CHIP did not increase the risk of AR, CLAD, or death in lung recipients.]]></summary>
        <author>
            <name>Aparna C Swaminathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Determinants of mosaic chromosomal alteration fitness]]></title>
        <id>pubmed:37905118</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37905118/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is characterized by the acquisition of a somatic mutation in a hematopoietic stem cell that results in a clonal expansion. These driver mutations can be single nucleotide variants in cancer driver genes or larger structural rearrangements called mosaic chromosomal alterations (mCAs). The factors that influence the variations in mCA fitness and ultimately result in different clonal expansion rates are not well-understood. We used the Passenger-Approximated Clonal...]]></summary>
        <author>
            <name>Yash Pershad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and somatic drivers in inherited hematologic malignancies]]></title>
        <id>pubmed:37904876</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904876/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited hematologic malignancies are linked to a heterogenous group of genes, knowledge of which is rapidly expanding using panel-based next-generation sequencing (NGS) or whole-exome/whole-genome sequencing. Importantly, the penetrance for these syndromes is incomplete, and disease development, progression or transformation has critical clinical implications. With the earlier detection of healthy carriers and sequential monitoring of these patients, clonal hematopoiesis and somatic driver...]]></summary>
        <author>
            <name>Julian Zoller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients]]></title>
        <id>pubmed:37904125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Lung recipients have a higher prevalence of CHIP and a larger variety of genes with CHIP-associated mutations compared with previous reports for the general population. CHIP did not increase the risk of AR, CLAD, or death in lung recipients.]]></summary>
        <author>
            <name>Aparna C Swaminathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Determinants of mosaic chromosomal alteration fitness]]></title>
        <id>pubmed:37905118</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37905118/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is characterized by the acquisition of a somatic mutation in a hematopoietic stem cell that results in a clonal expansion. These driver mutations can be single nucleotide variants in cancer driver genes or larger structural rearrangements called mosaic chromosomal alterations (mCAs). The factors that influence the variations in mCA fitness and ultimately result in different clonal expansion rates are not well-understood. We used the Passenger-Approximated Clonal...]]></summary>
        <author>
            <name>Yash Pershad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Germline and somatic drivers in inherited hematologic malignancies]]></title>
        <id>pubmed:37904876</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904876/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inherited hematologic malignancies are linked to a heterogenous group of genes, knowledge of which is rapidly expanding using panel-based next-generation sequencing (NGS) or whole-exome/whole-genome sequencing. Importantly, the penetrance for these syndromes is incomplete, and disease development, progression or transformation has critical clinical implications. With the earlier detection of healthy carriers and sequential monitoring of these patients, clonal hematopoiesis and somatic driver...]]></summary>
        <author>
            <name>Julian Zoller</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients]]></title>
        <id>pubmed:37904125</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904125/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Lung recipients have a higher prevalence of CHIP and a larger variety of genes with CHIP-associated mutations compared with previous reports for the general population. CHIP did not increase the risk of AR, CLAD, or death in lung recipients.]]></summary>
        <author>
            <name>Aparna C Swaminathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly]]></title>
        <id>pubmed:37904927</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904927/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging studies underscore the promising capabilities of large language model-based chatbots in conducting fundamental bioinformatics data analyses. The recent feature of accepting image-inputs by ChatGPT motivated us to explore its efficacy in deciphering bioinformatics illustrations. Our evaluation with examples in cancer research, including sequencing data analysis, multimodal network-based drug repositioning, and tumor clonal evolution, revealed that ChatGPT can proficiently explain...]]></summary>
        <author>
            <name>Jinge Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly]]></title>
        <id>pubmed:37904927</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904927/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging studies underscore the promising capabilities of large language model-based chatbots in conducting fundamental bioinformatics data analyses. The recent feature of accepting image-inputs by ChatGPT motivated us to explore its efficacy in deciphering bioinformatics illustrations. Our evaluation with examples in cancer research, including sequencing data analysis, multimodal network-based drug repositioning, and tumor clonal evolution, revealed that ChatGPT can proficiently explain...]]></summary>
        <author>
            <name>Jinge Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly]]></title>
        <id>pubmed:37904927</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904927/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging studies underscore the promising capabilities of large language model-based chatbots in conducting fundamental bioinformatics data analyses. The recent feature of accepting image-inputs by ChatGPT motivated us to explore its efficacy in deciphering bioinformatics illustrations. Our evaluation with examples in cancer research, including sequencing data analysis, multimodal network-based drug repositioning, and tumor clonal evolution, revealed that ChatGPT can proficiently explain...]]></summary>
        <author>
            <name>Jinge Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly]]></title>
        <id>pubmed:37904927</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904927/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging studies underscore the promising capabilities of large language model-based chatbots in conducting fundamental bioinformatics data analyses. The recent feature of accepting image-inputs by ChatGPT motivated us to explore its efficacy in deciphering bioinformatics illustrations. Our evaluation with examples in cancer research, including sequencing data analysis, multimodal network-based drug repositioning, and tumor clonal evolution, revealed that ChatGPT can proficiently explain...]]></summary>
        <author>
            <name>Jinge Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bioinformatics Illustrations Decoded by ChatGPT: The Good, The Bad, and The Ugly]]></title>
        <id>pubmed:37904927</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37904927/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-31T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging studies underscore the promising capabilities of large language model-based chatbots in conducting fundamental bioinformatics data analyses. The recent feature of accepting image-inputs by ChatGPT motivated us to explore its efficacy in deciphering bioinformatics illustrations. Our evaluation with examples in cancer research, including sequencing data analysis, multimodal network-based drug repositioning, and tumor clonal evolution, revealed that ChatGPT can proficiently explain...]]></summary>
        <author>
            <name>Jinge Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Differences in cell shape, motility, and growth reflect chromosomal number variations that can be visualized with live-cell ChReporters]]></title>
        <id>pubmed:37903225</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37903225/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chromosome numbers often change dynamically in tumors and in cultured cells, which complicates therapy as well as understanding genotype-mechanotype relationships. Here we use a live-cell 'ChReporter' method to identify cells with a single chromosomal loss in efforts to better understand differences in cell shape, motility, and growth. We focus on a standard lung cancer line and first show clonal populations that retain the ChReporter exhibit large differences in cell and nuclear morphology as...]]></summary>
        <author>
            <name>Michael P Tobin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Leukemic transformation during anti-tuberculosis treatment in aplastic anemia-paroxysmal nocturnal hemoglobinuria syndrome: A case report and review of literature]]></title>
        <id>pubmed:37901004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37901004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-30T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Aggravated inflammatory stressors can repress normal and leukemic hematopoiesis, and relieved inflammatory stressors can facilitate penetration of neoplastic hematopoiesis.]]></summary>
        <author>
            <name>Nuan-Nuan Xiu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering Potential Molecular Signatures to Differentiate Acute Myeloid Leukemia (AML) with <em>BCR::ABL1</em> from Chronic Myeloid Leukemia (CML) in Blast Crisis]]></title>
        <id>pubmed:37895120</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895120/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) with BCR::ABL1 has recently been recognized as a distinct subtype in international classifications. Distinguishing it from myeloid blast crisis chronic myeloid leukemia (BC-CML) without evidence of a chronic phase (CP), remains challenging. We aimed to better characterize this entity by integrating clonal architecture analysis, mutational landscape assessment, and gene expression profiling. We analyzed a large retrospective cohort study including CML and AML...]]></summary>
        <author>
            <name>Lara Boucher</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Emerging Insights into Molecular Mechanisms of Inflammation in Myelodysplastic Syndromes]]></title>
        <id>pubmed:37892987</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37892987/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Inflammation impacts human hematopoiesis across physiologic and pathologic conditions, as signals derived from the bone marrow microenvironment, such as pro-inflammatory cytokines and chemokines, have been shown to alter hematopoietic stem cell (HSCs) homeostasis. Dysregulated inflammation can skew HSC fate-related decisions, leading to aberrant hematopoiesis and potentially contributing to the pathogenesis of hematological disorders such as myelodysplastic syndromes (MDS). Recently, emerging...]]></summary>
        <author>
            <name>Veronica Vallelonga</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Adaptive therapy: a tumor therapy strategy based on Darwinian evolution theory]]></title>
        <id>pubmed:37898477</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37898477/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer progression is a dynamic process of continuous evolution, in which genetic diversity and heterogeneity are generated by clonal and subclonal amplification based on random mutations. Traditional cancer treatment strategies have a great challenge, which often leads to treatment failure due to drug resistance. Integrating evolutionary dynamics into treatment regimens may be an effective way to overcome the problem of drug resistance. In particular, a potential treatment is adaptive therapy,...]]></summary>
        <author>
            <name>Lei Zhang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Decoding Cancer Evolution: Integrating Genetic and Non-Genetic Insights]]></title>
        <id>pubmed:37895205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The development of cancer begins with cells transitioning from their multicellular nature to a state akin to unicellular organisms. This shift leads to a breakdown in the crucial regulators inherent to multicellularity, resulting in the emergence of diverse cancer cell subpopulations that have enhanced adaptability. The presence of different cell subpopulations within a tumour, known as intratumoural heterogeneity (ITH), poses challenges for cancer treatment. In this review, we delve into the...]]></summary>
        <author>
            <name>Arghavan Ashouri</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Hematologic Neoplasms Associated with Down Syndrome: Cellular and Molecular Heterogeneity of the Diseases]]></title>
        <id>pubmed:37895004</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37895004/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The molecular basis of Down syndrome (DS) predisposition to leukemia is not fully understood but involves various factors such as chromosomal abnormalities, oncogenic mutations, epigenetic alterations, and changes in selection dynamics. Myeloid leukemia associated with DS (ML-DS) is preceded by a preleukemic phase called transient abnormal myelopoiesis driven by GATA1 gene mutations and progresses to ML-DS via additional mutations in cohesin genes, CTCF, RAS, or JAK/STAT pathway genes....]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Overview of Tumor Heterogeneity in High-Grade Serous Ovarian Cancers]]></title>
        <id>pubmed:37894756</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37894756/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ovarian cancers encompass a group of neoplasms originating from germinal tissues and exhibiting distinct clinical, pathological, and molecular features. Among these, epithelial ovarian cancers (EOCs) are the most prevalent, comprising five distinct tumor histotypes. Notably, high-grade serous ovarian cancers (HGSOCs) represent the majority, accounting for over 70% of EOC cases. Due to their silent and asymptomatic behavior, HGSOCs are generally diagnosed in advanced stages with an evolved and...]]></summary>
        <author>
            <name>Eros Azzalini</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Alterations of the expression of TET2 and DNA 5-hmC predict poor prognosis in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37884893</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37884893/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-26T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: IPSS-R higher-risk MDS categories and AML-MR showed a reduction in TET2 expression, which was not apparent in lower-risk MDS. DNA 5-hmC levels followed a similar pattern. Overall, a decreased TET2 expression and a low DNA 5-hmC level are predictors of advanced disease and adverse outcome in MDS in the population studied, i.e., MDS patients from India.]]></summary>
        <author>
            <name>Ashikh A Seethy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal hematopoiesis and inflammation: A review of mechanisms and clinical implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis and Inflammation: A Review of Mechanisms and Clinical Implications]]></title>
        <id>pubmed:37879493</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37879493/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH) is defined by the presence of somatic mutations in hematopoietic stem and progenitor cells (HSPC). CH is associated primarily with advancing age and confers an elevated risk of progression to overt hematologic malignancy and cardiovascular disease. Increasingly, CH is associated with a wide range of diseases driven by, and sequelae of, inflammation. Accordingly, there is great interest in better understanding the pathophysiologic and clinical relationship between CH,...]]></summary>
        <author>
            <name>Daniel I Nathan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Temporal and structural patterns of hepatitis B virus integrations in hepatocellular carcinoma]]></title>
        <id>pubmed:37877809</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37877809/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Chronic infection of hepatitis B virus (HBV) is the major cause of hepatocellular carcinoma (HCC). Notably, 90% of HBV-positive HCC cases exhibit detectable HBV integrations, hinting at the potential early entanglement of these viral integrations in tumorigenesis and their subsequent oncogenic implications. Nevertheless, the precise chronology of integration events during HCC tumorigenesis, alongside their sequential structural patterns, has remained elusive thus far. In this study, we applied...]]></summary>
        <author>
            <name>Haozhen Ren</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[<em>SETD2</em> mutations do not contribute to clonal fitness in response to chemotherapy in childhood B cell acute lymphoblastic leukemia]]></title>
        <id>pubmed:37874744</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37874744/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mutations in genes encoding epigenetic regulators are commonly observed at relapse in B cell acute lymphoblastic leukemia (B-ALL). Loss-of-function mutations in SETD2, an H3K36 methyltransferase, have been observed in B-ALL and other cancers. Previous studies on mutated SETD2 in solid tumors and acute myelogenous leukemia support a role in promoting resistance to DNA damaging agents. We did not observe chemoresistance, an impaired DNA damage response, nor increased mutation frequency in response...]]></summary>
        <author>
            <name>Gloria P Contreras Yametti</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Growth Dynamics of Ductal Carcinoma in Situ Recapitulate Normal Breast Development]]></title>
        <id>pubmed:37873488</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873488/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Ductal carcinoma in situ (DCIS) and invasive breast cancer share many morphologic, proteomic, and genomic alterations. Yet in contrast to invasive cancer, many DCIS tumors do not progress and may remain indolent over decades. To better understand the heterogenous nature of this disease, we reconstructed the growth dynamics of 18 DCIS tumors based on the geo-spatial distribution of their somatic mutations. The somatic mutation topographies revealed that DCIS is multiclonal and consists of...]]></summary>
        <author>
            <name>Marc D Ryser</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Characterization of Cancer Evolution Landscape Based on Accurate Detection of Somatic Mutations in Single Tumor Cells]]></title>
        <id>pubmed:37873375</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37873375/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate detection of somatic mutations in single tumor cells is greatly desired as it allows us to quantify the single-cell mutation burden and construct the mutation-based phylogenetic tree. Here we developed scNanoSeq chemistry and profiled 842 single cells from 21 human breast cancer samples. The majority of the mutation-based phylogenetic trees comprise a characteristic stem evolution followed by the clonal sweep. We observed the subtype-dependent lengths in the stem evolution. To explain...]]></summary>
        <author>
            <name>Muchun Niu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A guide to epigenetics in leukaemia stem cells]]></title>
        <id>pubmed:37872885</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37872885/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-24T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Leukaemia stem cells (LSCs) are the critical seed for the growth of haematological malignancies, driving the clonal expansion that enables disease initiation, relapse and often resistance. Specifically, they display inherent phenotypic and epigenetic plasticity resulting in complex heterogenic diseases. In this review, we discuss the key principles of deregulation of epigenetic processes that shape this disease evolution. We consider measures to define and quantify clonal heterogeneity,...]]></summary>
        <author>
            <name>Shuchi Agrawal-Singh</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231103204955&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Refphase: Multi-sample phasing reveals haplotype-specific copy number heterogeneity]]></title>
        <id>pubmed:37871126</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37871126/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Most computational methods that infer somatic copy number alterations (SCNAs) from bulk sequencing of DNA analyse tumour samples individually. However, the sequencing of multiple tumour samples from a patient's disease is an increasingly common practice. We introduce Refphase, an algorithm that leverages this multi-sampling approach to infer haplotype-specific copy numbers through multi-sample phasing. We demonstrate Refphase's ability to infer haplotype-specific SCNAs and characterise their...]]></summary>
        <author>
            <name>Thomas B K Watkins</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[TFH lymphoma and associated clonal hematopoiesis]]></title>
        <id>pubmed:37870568</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37870568/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tfollicular helper (TFH) cell lymphoma (TFHL) is a lymphoma of mature T cells with phenotypic characteristics and gene expression signature of TFH cells. The lymphoma harbors recurrent mutations of RHOA^(G17V), IDH2^(R172), TET2 and DNMT3A. Whereas RHOA^(G17V) and IDH2^(R172) are almost exclusively found in this entity, TET2 and DNMT3A mutations occur in a broad variety of hematological neoplasms and are the most frequently affected genes in clonal hematopoiesis (CH). CH in humans shows a...]]></summary>
        <author>
            <name>Dominik Nann</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231104205408&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231103204956&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute Myeloid Leukemia Arising from Myelodysplastic Syndromes]]></title>
        <id>pubmed:37865509</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865509/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by clonal hematopoiesis and abnormal maturation of hematopoietic cells, resulting in cytopenias. The transformation of MDS to acute myeloid leukemia (AML) reflects a progressive increase in blasts due to impaired maturation of the malignant clone, and thus MDS and many AML subtypes form a biological continuum rather than representing two distinct diseases. Recent data suggest that, in addition to previously described...]]></summary>
        <author>
            <name>Adelaide Kwon</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Premalignant Clonal Hematopoiesis (Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance)]]></title>
        <id>pubmed:37865503</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37865503/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Premalignant clonal hematopoiesis is the presence of somatic alterations in the blood of otherwise healthy individuals. Although the condition is not considered as a cancer, it carries an increased risk of developing a hematologic malignancy, particularly in those with large neoplastic clones, multiple pathogenic mutations, and high-risk mutations. In addition to the increased risk of malignancy, clonal hematopoiesis carries a markedly increased risk of cardiovascular events and death....]]></summary>
        <author>
            <name>Kelly E Craven</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231102205033&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[SRCAP mutations drive clonal hematopoiesis through epigenetic and DNA repair dysregulation]]></title>
        <id>pubmed:37863054</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37863054/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic mutations accumulate in all cells with age and can confer a selective advantage, leading to clonal expansion over time. In hematopoietic cells, mutations in a subset of genes regulating DNA repair or epigenetics frequently lead to clonal hematopoiesis (CH). Here, we describe the context and mechanisms that lead to enrichment of hematopoietic stem cells (HSCs) with mutations in SRCAP, which encodes a chromatin remodeler that also influences DNA repair. We show that SRCAP mutations confer...]]></summary>
        <author>
            <name>Chun-Wei Chen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A pan-cancer landscape of pathogenic somatic copy number variations]]></title>
        <id>pubmed:37858853</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858853/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study contributes to elucidate the functional impact of pathogenic CNVs in tumor progression and sheds light on their potential as prognostic markers in specific cancer types.]]></summary>
        <author>
            <name>Tommaso Becchi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Oligo-metastatic neoPlasms from the gastro-intestinal tract: iDentIfiCaTIon of cliNical and molecular drivers: the PREDICTION study]]></title>
        <id>pubmed:37858132</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37858132/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[BACKGROUND: Metastatic disease in tumors originating from the gastrointestinal tract can exhibit varying degrees of tumor burden at presentation. Some patients follow a less aggressive disease course, characterized by a limited number of metastatic sites, referred to as "oligo-metastatic disease" (OMD). The precise biological characteristics that define the oligometastatic behavior remain uncertain. In this study, we present a protocol designed to prospectively identify OMD, with the aim of...]]></summary>
        <author>
            <name>Alessandro Ottaiano</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A mouse model with high clonal barcode diversity for joint lineage, transcriptomic, and epigenomic profiling in single cells]]></title>
        <id>pubmed:37852258</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37852258/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-18T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cellular lineage histories and their molecular states encode fundamental principles of tissue development and homeostasis. Current lineage-recording mouse models have insufficient barcode diversity and single-cell lineage coverage for profiling tissues composed of millions of cells. Here, we developed DARLIN, an inducible Cas9 barcoding mouse line that utilizes terminal deoxynucleotidyl transferase (TdT) and 30 CRISPR target sites. DARLIN is inducible, generates massive lineage barcodes across...]]></summary>
        <author>
            <name>Li Li</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231101205012&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The Role of Non-Coding RNAs in Myelodysplastic Neoplasms]]></title>
        <id>pubmed:37835504</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37835504/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes or neoplasms (MDS) are a heterogeneous group of myeloid clonal disorders characterized by peripheral blood cytopenias, blood and marrow cell dysplasia, and increased risk of evolution to acute myeloid leukemia (AML). Non-coding RNAs, especially microRNAs and long non-coding RNAs, serve as regulators of normal and malignant hematopoiesis and have been implicated in carcinogenesis. This review presents a comprehensive summary of the biology and role of non-coding RNAs,...]]></summary>
        <author>
            <name>Vasileios Georgoulis</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231031205323&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Technology of genomic balancing of chromatin of autologous hematopoietic stem cells for gene therapy of fatal immune-mediated diseases of civilization, extended life expectancy and sudden human death prevention]]></title>
        <id>pubmed:37833013</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37833013/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A biotechnology for personalized ex vivo gene therapy based on molecular genomic balancing of hematopoietic stem cell (HSC) chromatin with nucleosome monomers of human genomic DNA (hDNA^(nmr)) has been developed and implemented in the clinic to change (to "correct") mutant chromosome loci genomes of dominant HSC clones that form mono- and oligoclonal hematopoiesis during aging and major (oncological, cardiovascular, neurodegenerative and autoimmune) fatal immune-mediated diseases of...]]></summary>
        <author>
            <name>A S Bryukhovetskiy</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis, Inflammation, and Hematologic Malignancy]]></title>
        <id>pubmed:37832948</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37832948/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-13T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic or acquired mutations are postzygotic genetic variations that can occur within any tissue. These mutations accumulate during aging and have classically been linked to malignant processes. Tremendous advancements over the past years have led to a deeper understanding of the role of somatic mutations in benign and malignant age-related diseases. Here, we review the somatic mutations that accumulate in the blood and their connection to disease states, with a particular focus on inflammatory...]]></summary>
        <author>
            <name>Rashmi Kanagal-Shamanna</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies]]></title>
        <id>pubmed:37827894</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37827894/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal and differentiation. The increasing use of induced pluripotent stem cell (iPSC) technology to study myeloid malignancies has helped usher a paradigm shift in approaches to disease modeling and drug discovery, especially when combined with gene-editing technology. The process of...]]></summary>
        <author>
            <name>Dharamveer Tatwavedi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Targeted single-cell RNA sequencing analysis reveals metabolic reprogramming and the ferroptosis-resistant state in hematologic malignancies]]></title>
        <id>pubmed:37823726</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37823726/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematologic malignancies are the most common hematopoietic diseases and a major public health concern. However, the mechanisms underlying myeloid tumors remain unknown owing to the intricate interplay between mutations and diverse clonal evolution patterns, as evidenced by the analysis of bulk cell-derived omics data. Several single-cell omics techniques have been used to characterize the hierarchies and altered immune microenvironments of hematologic malignancies. The comprehensive single-cell...]]></summary>
        <author>
            <name>Xiaohui Shen</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Phertilizer: Growing a clonal tree from ultra-low coverage single-cell DNA sequencing of tumors]]></title>
        <id>pubmed:37819942</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37819942/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Emerging ultra-low coverage single-cell DNA sequencing (scDNA-seq) technologies have enabled high resolution evolutionary studies of copy number aberrations (CNAs) within tumors. While these sequencing technologies are well suited for identifying CNAs due to the uniformity of sequencing coverage, the sparsity of coverage poses challenges for the study of single-nucleotide variants (SNVs). In order to maximize the utility of increasingly available ultra-low coverage scDNA-seq data and obtain a...]]></summary>
        <author>
            <name>Leah L Weber</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231030205036&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[STING activation in TET2-mutated hematopoietic stem/progenitor cells contributes to the increased self-renewal and neoplastic transformation]]></title>
        <id>pubmed:37816954</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37816954/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-10T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Somatic loss-of-function mutations of the dioxygenase Ten-eleven translocation-2 (TET2) occur frequently in individuals with clonal hematopoiesis (CH) and acute myeloid leukemia (AML). These common hematopoietic disorders can be recapitulated in mouse models. However, the underlying mechanisms by which the deficiency in TET2 promotes these disorders remain unclear. Here we show that the cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS)-stimulator of interferon genes (STING)...]]></summary>
        <author>
            <name>Jiaying Xie</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231029205030&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231028205254&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplastic Syndrome After Anti-CD19 Chimeric Antigen Receptor T-cell Therapy: A Case Series]]></title>
        <id>pubmed:37809221</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37809221/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The utility of CD19-targeted chimeric antigen receptor T-cell (CAR-T cell) therapy in the management of refractory/relapsed B-cell malignancies has increased tremendously in recent times. In addition to cytokine release syndrome (CRS), neurotoxicity, and infections, CAR-T cell patients develop cytopenias, with about 15% of the patients continuing to have severe cytopenias up to three months after treatment. Retrospective reviews have reported the development of myelodysplastic syndrome (MDS) in...]]></summary>
        <author>
            <name>Armaan Dhaliwal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Subclonal Somatic Copy-Number Alterations Emerge and Dominate in Recurrent Osteosarcoma]]></title>
        <id>pubmed:37812025</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37812025/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Multiple large-scale genomic profiling efforts have been undertaken in osteosarcoma to define the genomic drivers of tumorigenesis, therapeutic response, and disease recurrence. The spatial and temporal intratumor heterogeneity could also play a role in promoting tumor growth and treatment resistance. We conducted longitudinal whole-genome sequencing of 37 tumor samples from 8 patients with relapsed or refractory osteosarcoma. Each patient had at least one sample from a primary site and a...]]></summary>
        <author>
            <name>Michael D Kinnaman</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) is a heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but does not adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) are heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but don't adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) are heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but don't adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bomedemstat as an investigative treatment for myeloproliferative neoplasms]]></title>
        <id>pubmed:37804041</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37804041/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-07T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[INTRODUCTION: Myeloproliferative neoplasm (MPN) are heterogeneous group of hematopoietic stem cell disorders characterized by clonal proliferation of one of more of the hematopoietic stem cell lineages. Clinical manifestations result from uncontrolled myeloproliferation, extramedullary hematopoiesis with splenomegaly and excessive inflammatory cytokine production. Currently available therapy improves hematologic parameters and symptoms but don't adequately address the underlying neoplastic...]]></summary>
        <author>
            <name>Hugh Young Rienhoff</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231027204803&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients]]></title>
        <id>pubmed:37799345</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37799345/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Recent evidence revealed important interactions between clonal hematopoiesis (CH) and cellular therapies established for the treatment of hematologic malignancies. The impact of CH on safety, efficacy, and outcome of chimeric antigen receptor (CAR) T-cell therapy is currently under investigation. We analyzed 110 patients with relapsed/refractory B-cell non-Hodgkin lymphoma (n = 105) or acute lymphoblastic leukemia (ALL) (n = 5), treated with Axicabtagene-Ciloleucel (39%), Tisagenlecleucel (51%),...]]></summary>
        <author>
            <name>Victoria Panagiota</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231027204802&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Acute myeloid leukemia: from NGS, through scRNA-seq, to CAR-T. dissect cancer heterogeneity and tailor the treatment]]></title>
        <id>pubmed:37803464</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803464/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Acute myeloid leukemia (AML) is a malignant blood cancer with marked cellular heterogeneity due to altered maturation and differentiation of myeloid blasts, the possible causes of which are transcriptional or epigenetic alterations, impaired apoptosis, and excessive cell proliferation. This neoplasm has a high rate of resistance to anticancer therapies and thus a high risk of relapse and mortality because of both the biological diversity of the patient and intratumoral heterogeneity due to the...]]></summary>
        <author>
            <name>Edoardo Peroni</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Small extrachromosomal circular DNA harboring targeted tumor suppressor gene mutations supports intratumor heterogeneity in mouse liver cancer induced by multiplexed CRISPR/Cas9]]></title>
        <id>pubmed:37803452</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37803452/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-06T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Small eccDNAs carrying TSG mutations may serve as an important source supporting intratumor heterogeneity and tumor evolution in mouse liver cancer induced by multiplexed CRISPR/Cas9.]]></summary>
        <author>
            <name>Tao Guo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive genomic characterization of sporadic synchronous colorectal cancer: Implications for treatment optimization and clinical outcome]]></title>
        <id>pubmed:37794586</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794586/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-05T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Sporadic synchronous colorectal cancer (SCRC) refers to multiple primary CRC tumors detected simultaneously in an individual without predisposing hereditary conditions, which accounts for the majority of multiple CRCs while lacking a profound understanding of the genomic landscape and evolutionary dynamics to optimize its treatment. In this study, 103 primary tumor samples from 51 patients with SCRC undergo whole-exome sequencing. The germline and somatic mutations and evolutionary and clinical...]]></summary>
        <author>
            <name>Lu-Ping Yang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Rare variant associations with plasma protein levels in the UK Biobank]]></title>
        <id>pubmed:37794183</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794183/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231026204906&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Integrating human genomics and proteomics can help elucidate disease mechanisms, identify clinical biomarkers and discover drug targets^(1-4). Because previous proteogenomic studies have focused on common variation via genome-wide association studies, the contribution of rare variants to the plasma proteome remains largely unknown. Here we identify associations between rare protein-coding variants and 2,923 plasma protein abundances measured in 49,736 UK Biobank individuals. Our variant-level...]]></summary>
        <author>
            <name>Ryan S Dhindsa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231025204855&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231024204954&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231023204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Immune pathophysiology of bone marrow failure]]></title>
        <id>pubmed:37793865</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793865/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Bone marrow (BM) failure is a condition characterized by peripheral pancytopenia due to decreased BM function. It includes conditions such as acquired aplastic anemia (AA), myelodysplastic syndrome (MDS), and paroxysmal nocturnal hemoglobinuria (PNH). AA is characterized by pancytopenia and BM hypoplasia, and is primarily caused by an autoimmune mechanism involving cytotoxic T cells that damage hematopoietic stem cells (HSCs). Recent genomic research has revealed that patients with AA often...]]></summary>
        <author>
            <name>Kohei Hosokawa</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Human diseases and the mechanisms regulating myelopoiesis]]></title>
        <id>pubmed:37793858</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793858/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelopoiesis is a process that produces myeloid cells including granulocytes and mononuclear phagocytes. The differentiation and proliferation of hematopoietic stem and progenitor cells are tightly regulated to meet demands for such myeloid cells both at steady state and under stressed conditions. CCAAT/enhancer-binding protein family transcription factors are involved not only in the appropriate regulation of myelopoiesis but also in dysregulated myelopoiesis. A recent study has revealed that...]]></summary>
        <author>
            <name>Hideyo Hirai</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231023204959&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genomic signatures of past and present chromosomal instability in Barrett's esophagus and early esophageal adenocarcinoma]]></title>
        <id>pubmed:37794034</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794034/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The progression of precancerous lesions to malignancy is often accompanied by increasing complexity of chromosomal alterations but how these alterations arise is poorly understood. Here we perform haplotype-specific analysis of chromosomal copy-number evolution in the progression of Barrett's esophagus (BE) to esophageal adenocarcinoma (EAC) on multiregional whole-genome sequencing data of BE with dysplasia and microscopic EAC foci. We identify distinct patterns of copy-number evolution...]]></summary>
        <author>
            <name>Chunyang Bao</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Deciphering treatment patterns in non-severe/moderate aplastic anemia: an international observational study]]></title>
        <id>pubmed:37794100</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37794100/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Non-severe aplastic anemia is a rare bone marrow failure disorder characterized by variable degrees and combination of cytopenias, with limited data on management and outcome. We describe a large multicentric series of 259 patients, focusing on clinical and molecular features, treatment, evolution, and survival. The majority required treatment with cyclosporine (CyA) alone (N = 84) or in combination with anti-thymocyte globulin (ATG,44) or eltrombopag (20), eltrombopag alone (10), or others (25)...]]></summary>
        <author>
            <name>Bruno Fattizzo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myeloid neoplasms with germline predisposition]]></title>
        <id>pubmed:37793870</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37793870/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[With recent advances in sequencing technologies, novel genes associated with the predisposition to myeloid neoplasms have been discovered, and subsequent studies have shown that the incidence of myeloid neoplasms associated with germline variants is higher than expected. Accordingly, myeloid neoplasms with germline predisposition have represented a unique category in the recent WHO classification and the International Consensus Classification, and DDX41 mutation accounts for 2-5% of myeloid...]]></summary>
        <author>
            <name>Kenichi Yoshida</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Identifying predictors of glioma evolution from longitudinal sequencing]]></title>
        <id>pubmed:37792958</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37792958/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-04T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal evolution drives cancer progression and therapeutic resistance. Recent studies have revealed divergent longitudinal trajectories in gliomas, but early molecular features steering posttreatment cancer evolution remain unclear. Here, we collected sequencing and clinical data of initial-recurrent tumor pairs from 544 adult diffuse gliomas and performed multivariate analysis to identify early molecular predictors of tumor evolution in three diffuse glioma subtypes. We found that CDKN2A...]]></summary>
        <author>
            <name>Quanhua Mu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Success of Liquid Tumor Biopsy in Men with Metastatic Prostate Cancer According to Self-Identified Race]]></title>
        <id>pubmed:37785441</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37785441/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Successful cfDNA biopsy in metastatic PrCa is associated with PSA and PSADT, but not related to patient self-identified race. In appropriate clinical scenarios, patients who self-identify as Black or White are equally likely to have PrCa-specific alterations detected on cfDNA testing when evaluating metastatic PrCa patients for local and systemic therapies.]]></summary>
        <author>
            <name>L Valle</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Evolutionary fingerprints of EMT in pancreatic cancers]]></title>
        <id>pubmed:37786705</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37786705/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-03T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Mesenchymal plasticity has been extensively described in advanced and metastatic epithelial cancers; however, its functional role in malignant progression, metastatic dissemination and therapy response is controversial. More importantly, the role of epithelial mesenchymal transition (EMT) and cell plasticity in tumor heterogeneity, clonal selection and clonal evolution is poorly understood. Functionally, our work clarifies the contribution of EMT to malignant progression and metastasis in...]]></summary>
        <author>
            <name>Luigi Perelli</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in <em>Tet2</em> Clonal Hematopoiesis]]></title>
        <id>pubmed:37781816</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37781816/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Hypercholesterolemia and TET2 deficiency converge on a common pathway of NLRP3 inflammasome activation mediated by JNK1 activation and BRCC3-mediated NLRP3 deubiquitylation, with potential therapeutic implications for the prevention of cardiovascular disease in TET2 CH.]]></summary>
        <author>
            <name>Mustafa Yalcinkaya</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231022205027&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Somatic evolution of marine transmissible leukemias in the common cockle, Cerastoderma edule]]></title>
        <id>pubmed:37783803</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37783803/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-02T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Transmissible cancers are malignant cell lineages that spread clonally between individuals. Several such cancers, termed bivalve transmissible neoplasia (BTN), induce leukemia-like disease in marine bivalves. This is the case of BTN lineages affecting the common cockle, Cerastoderma edule, which inhabits the Atlantic coasts of Europe and northwest Africa. To investigate the evolution of cockle BTN, we collected 6,854 cockles, diagnosed 390 BTN tumors, generated a reference genome and assessed...]]></summary>
        <author>
            <name>Alicia L Bruzos</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231021205333&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genome-First Approach of the Prevalence and Cancer Phenotypes of Pathogenic or Likely Pathogenic Germline TP53 Variants]]></title>
        <id>pubmed:37777824</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37777824/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-10-01T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Pathogenic or likely pathogenic (P/LP) germline TP53 variants are the primary cause of Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder characterized by early-onset cancers. The population prevalence of P/LP germline TP53 variants is estimated to be approximately one in every 3,500-20,000 individuals. However, these estimates are likely impacted by ascertainment biases and lack of clinical and genetic data to account for potential confounding factors, such as clonal...]]></summary>
        <author>
            <name>Kelvin C de Andrade</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231020204820&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Diagnosis and classification of myelodysplastic syndromes]]></title>
        <id>pubmed:37774372</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37774372/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-29T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelodysplastic syndromes (MDSs) are neoplastic myeloid proliferations characterized by ineffective hematopoiesis resulting in peripheral blood cytopenias. MDS is distinguished from non-neoplastic clonal myeloid proliferations by the presence of morphologic dysplasia and from acute myeloid leukemia (AML) by a blast threshold of 20%. The diagnosis of MDS can be challenging due to the myriad other causes of cytopenias: accurate diagnosis requires the integration of clinical features with bone...]]></summary>
        <author>
            <name>Robert P Hasserjian</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The spectrum of glomerular and vascular kidney pathology associated with myeloproliferative neoplasms]]></title>
        <id>pubmed:37769965</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37769965/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[A high prevalence of chronic kidney disease (CKD) occurs in patients with myeloproliferative neoplasms (MPN). However, MPN-related glomerulopathy (MPN-RG) may not account for the entirety of CKD risk in this population. The systemic vasculopathy encountered in these patients raises the hypothesis that vascular nephrosclerosis may be a common pattern of injury in patients with MPN and with CKD. In an exhaustive, retrospective, multicenter study of MPN kidney biopsies in four different pathology...]]></summary>
        <author>
            <name>Thibaut d'Izarny-Gargas</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential and Cardiovascular Risk in Patients with Chronic Kidney Disease without Previous Cardiac Pathology]]></title>
        <id>pubmed:37763205</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37763205/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the clonal expansion of hematopoietic stem cells carrying certain genes associated with an increased risk of hematological malignancies. Our study analyzes the influence of CHIP on the risk of heart disease and cardiovascular events in a population with chronic kidney disease (CKD). A total of 128 patients were prospectively followed up for 18 months to detect major cardiovascular events (MACE). To detect the presence of silent...]]></summary>
        <author>
            <name>Maria Kislikova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Exploring the Molecular Landscape of Myelofibrosis, with a Focus on Ras and Mitogen-Activated Protein (MAP) Kinase Signaling]]></title>
        <id>pubmed:37760623</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37760623/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-28T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Myelofibrosis (MF) is a clonal myeloproliferative neoplasm (MPN) characterized clinically by cytopenias, fatigue, and splenomegaly stemming from extramedullary hematopoiesis. MF commonly arises from mutations in JAK2, MPL, and CALR, which manifests as hyperactive Jak/Stat signaling. Triple-negative MF is diagnosed in the absence of JAK2, MPL, and CALR but when clinical, morphologic criteria are met and other mutation(s) is/are present, including ASXL1, EZH2, and SRSF2. While the clinical and...]]></summary>
        <author>
            <name>Samuel B Reynolds</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231012205120&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Runx1-R188Q germline mutation induces inflammation and predisposition to hematologic malignancies in mice]]></title>
        <id>pubmed:37756546</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756546/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Germline mutations in the RUNX1 gene cause familial platelet disorder (FPD), an inherited disease associated with lifetime risk to hematopoietic malignancies (HM). FPD patients frequently show clonal expansion of pre-malignant cells preceding HM onset. Despite the extensive studies on the role of RUNX1 in hematopoiesis, its function in the pre-malignant bone marrow is not well understood. Here, we characterized the hematopoietic progenitor compartments using a mouse strain carrying an...]]></summary>
        <author>
            <name>Mohd Hafiz Ahmad</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Incident Type 2 Diabetes Risk]]></title>
        <id>pubmed:37756531</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37756531/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CHIP was associated with higher incidence of T2D. CHIP mutations located on genes implicated in CHD and mortality were also related to T2D, suggesting shared aging-related pathology.]]></summary>
        <author>
            <name>Deirdre K Tobias</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231019204958&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231018205013&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231017205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231016205028&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231015205105&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231014205339&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer]]></title>
        <id>pubmed:37758711</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37758711/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[HER2-positive (HER2+) breast cancer accounts for 20-25% of all breast cancers. Predictive biomarkers of neoadjuvant therapy response are needed to better identify patients with early stage disease who may benefit from tailored treatments in the adjuvant setting. As part of the TCHL phase-II clinical trial (ICORG10-05/NCT01485926) whole exome DNA sequencing was carried out on normal-tumour pairs collected from 22 patients. Here we report predictive modelling of neoadjuvant therapy response using...]]></summary>
        <author>
            <name>Nicola Cosgrove</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Application of Induced Pluripotent Stem Cells in Malignant Solid Tumors]]></title>
        <id>pubmed:37755647</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37755647/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-27T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the past decade, induced pluripotent stem cells (iPSCs) technology has significantly progressed in studying malignant solid tumors. This technically feasible reprogramming techniques can reawaken sequestered dormant regions that regulate the fate of differentiated cells. Despite the evolving therapeutic modalities for malignant solid tumors, treatment outcomes have not been satisfactory. Recently, scientists attempted to apply induced pluripotent stem cell technology to cancer research, from...]]></summary>
        <author>
            <name>Rong He</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Newborn and child-like molecular signatures in older adults stem from TCR shifts across human lifespan]]></title>
        <id>pubmed:37749325</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749325/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CD8^(+) T cells provide robust antiviral immunity, but how epitope-specific T cells evolve across the human lifespan is unclear. Here we defined CD8^(+) T cell immunity directed at the prominent influenza epitope HLA-A*02:01-M1(58-66) (A2/M1(58)) across four age groups at phenotypic, transcriptomic, clonal and functional levels. We identify a linear differentiation trajectory from newborns to children then adults, followed by divergence and a clonal reset in older adults. Gene profiles in older...]]></summary>
        <author>
            <name>Carolien E van de Sandt</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell lineage capture across genomic modalities with CellTag-multi reveals fate-specific gene regulatory changes]]></title>
        <id>pubmed:37749269</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37749269/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Complex gene regulatory mechanisms underlie differentiation and reprogramming. Contemporary single-cell lineage-tracing (scLT) methods use expressed, heritable DNA barcodes to combine cell lineage readout with single-cell transcriptomics. However, reliance on transcriptional profiling limits adaptation to other single-cell assays. With CellTag-multi, we present an approach that enables direct capture of heritable random barcodes expressed as polyadenylated transcripts, in both single-cell RNA...]]></summary>
        <author>
            <name>Kunal Jindal</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clearing and replacing tissue-resident myeloid cells with an anti-CD45-antibody-drug conjugate]]></title>
        <id>pubmed:37748049</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37748049/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231013204816&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231012205121&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Comprehensive and realistic simulation of tumour genomic sequencing data]]></title>
        <id>pubmed:37746635</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37746635/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-25T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Accurate identification of somatic mutations and allele frequencies in cancer has critical research and clinical applications. Several computational tools have been developed for this purpose but, in the absence of comprehensive 'ground truth' data, assessing the accuracy of these methods is challenging. We created a computational framework to simulate tumour and matched normal sequencing data for which the source of all loci that contain non-reference bases is known, based on a phased,...]]></summary>
        <author>
            <name>Brian O'Sullivan</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231011204744&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal evolution of long-term expanding head and neck cancer organoid: Impact on treatment response for personalized therapeutic screening]]></title>
        <id>pubmed:37741019</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37741019/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-23T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: We report the establishment of HNCO lines derived from 27 patients and demonstrate their genetic concordance with corresponding parental tumors. Furthermore, we show serial changes in mutational profiles of HNCO along with long passage culture and the impact of these clonal evolutions on response to radiotherapy.]]></summary>
        <author>
            <name>Sung Yong Choi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231010204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231009204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis as a Molecular Risk Factor for Doxorubicin-Induced Cardiotoxicity: A Proof-of-Concept Study]]></title>
        <id>pubmed:37738545</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37738545/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-22T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: This study provides preliminary evidence for CH as a predictive risk factor for DIC, which, with further investigation, could serve as an important precision medicine biomarker for the large number of patients with cancer who have CH.]]></summary>
        <author>
            <name>Jamila Mammadova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231003205046&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[CD45-antibody-drug conjugate clears tissue resident myeloid cells from their niches enabling therapeutic adoptive cell transfer]]></title>
        <id>pubmed:37732224</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732224/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tissue resident myeloid cells (TRM) in adults have highly variable lifespans and may be derived from early embryonic yolk sac, fetal liver or bone marrow. Some of these TRM are known pathogenic participants in congenital and acquired diseases. Myeloablative conditioning and hematopoietic stem cell transplant can replace long-lived brain TRM resulting in clinical improvements in metabolic storage diseases. With the advent of antibody-drug-conjugate (ADC) targeted cell killing as a cell selective...]]></summary>
        <author>
            <name>Karin Gustafsson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Long-term longitudinal analysis of 4,187 participants reveals new insights into determinants of incident clonal hematopoiesis]]></title>
        <id>pubmed:37732181</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37732181/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-21T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH), characterized by blood cells predominantly originating from a single mutated hematopoietic stem cell, is linked to diverse aging-related diseases, including hematologic malignancy and atherosclerotic cardiovascular disease (ASCVD). While CH is common among older adults, the underlying factors driving its development are largely unknown. To address this, we performed whole-exome sequencing on 8,374 blood DNA samples collected from 4,187 Atherosclerosis Risk in...]]></summary>
        <author>
            <name>Md Mesbah Uddin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Impact of Preexisting Autoimmune Disease on Myelodysplastic Syndromes Outcomes: A population Analysis]]></title>
        <id>pubmed:37729616</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729616/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Preexisting autoimmune disease affects 10-30% of patients with myelodysplastic syndromes (MDS). Studies comparing outcomes in MDS patients with and without autoimmune disease show discordant results. Using Surveillance, Epidemiology, and End Results (SEER)-Medicare, we conducted a population analysis to define the impact of autoimmunity on MDS outcomes. Cases were ascertained between 2007 - 2017 and claim algorithms employed to identify autoimmune disease, demographic characteristics,...]]></summary>
        <author>
            <name>Diego Andres Adrianzen-Herrera</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Single-cell genotypic and phenotypic analysis of measurable residual disease in acute myeloid leukemia]]></title>
        <id>pubmed:37729414</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37729414/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Measurable residual disease (MRD), defined as the population of cancer cells that persist following therapy, serves as the critical reservoir for disease relapse in acute myeloid leukemia and other malignancies. Understanding the biology enabling MRD clones to resist therapy is necessary to guide the development of more effective curative treatments. Discriminating between residual leukemic clones, preleukemic clones, and normal precursors remains a challenge with current MRD tools. Here, we...]]></summary>
        <author>
            <name>Troy M Robinson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231008205021&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231007205329&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance]]></title>
        <id>pubmed:37730678</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37730678/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-20T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Tumor recognition by T cells is essential for antitumor immunity. A comprehensive characterization of T cell diversity may be key to understanding the success of immunomodulatory drugs and failure of PD-1 blockade in tumors such as multiple myeloma (MM). Here, we use single-cell RNA and T cell receptor sequencing to characterize bone marrow T cells from healthy adults (n = 4) and patients with precursor (n = 8) and full-blown MM (n = 10). Large T cell clones from patients with MM expressed...]]></summary>
        <author>
            <name>Cirino Botta</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231006204916&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance]]></title>
        <id>pubmed:37726835</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37726835/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSION: Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.]]></summary>
        <author>
            <name>Ao Liu</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Microfluidic design in single-cell sequencing and application to cancer precision medicine]]></title>
        <id>pubmed:37725985</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37725985/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-19T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Single-cell sequencing (SCS) is a crucial tool to reveal the genetic and functional heterogeneity of tumors, providing unique insights into the clonal evolution, microenvironment, drug resistance, and metastatic progression of cancers. Microfluidics is a critical component of many SCS technologies and workflows, conferring advantages in throughput, economy, and automation. Here, we review the current landscape of microfluidic architectures and sequencing techniques for single-cell omics analysis...]]></summary>
        <author>
            <name>Xin Han</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231005204957&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Genetic intra-tumour heterogeneity remodels the immune microenvironment and induces immune evasion in brain metastasis of lung cancer]]></title>
        <id>pubmed:37717855</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37717855/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-17T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: Our findings provide novel insights into the metastatic process and immune escape mechanisms of brain metastasis and pave the way for precise immunotherapeutic strategies for lung cancer patients with brain metastasis.]]></summary>
        <author>
            <name>Xin Wang</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[An Update on Inflammation in Atherosclerosis: How to Effectively Treat Residual Risk]]></title>
        <id>pubmed:37716836</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37716836/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[PURPOSE: This study reviewed the contribution of inflammation to atherosclerotic cardiovascular disease (ASCVD), which has gained widespread recognition in recent years.]]></summary>
        <author>
            <name>N Mohammadnia</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Interpretation of ambiguous TP53 test results: Mosaicism, clonal hematopoiesis, and variants of uncertain significance]]></title>
        <id>pubmed:37715966</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37715966/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-16T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[The increased use of next-generation sequencing has led to the detection of pathogenic TP53 variants in the germline setting in patients without a personal or family history consistent with Li-Fraumeni syndrome (LFS). These variants can represent low-penetrance LFS, mosaic LFS, or clonal hematopoiesis of indeterminate potential. Additionally, TP53 variants of uncertain significance can be detected in patients with a history suspicious for LFS. The interpretation of the significance of these...]]></summary>
        <author>
            <name>Darcy K Berry</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal cooperation through soluble metabolite exchange facilitates metastatic outgrowth by modulating Allee effect]]></title>
        <id>pubmed:37713487</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37713487/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-15T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancers feature substantial intratumoral heterogeneity of genetic and phenotypically distinct lineages. Although interactions between coexisting lineages are emerging as a potential contributor to tumor evolution, the extent and nature of these interactions remain largely unknown. We postulated that tumors develop ecological interactions that sustain diversity and facilitate metastasis. Using a combination of fluorescent barcoding, mathematical modeling, metabolic analysis, and in vivo models,...]]></summary>
        <author>
            <name>Benjamin J Hershey</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230928204947&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Ppm1d truncating mutations promote the development of genotoxic stress-induced AML]]></title>
        <id>pubmed:37709843</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37709843/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Hematopoietic stem cells (HSCs) ensure blood cell production during the life-time of an organism, and to do so they need to balance self-renewal, proliferation, differentiation, and migration in a steady state as well as in response to stress or injury. Importantly, aberrant proliferation of HSCs leads to hematological malignancies, and thus, tight regulation by various tumor suppressor pathways, including p53, is essential. Protein phosphatase magnesium-dependent 1 delta (PPM1D) is a negative...]]></summary>
        <author>
            <name>Monika Burocziova</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Bone Marrow Microenvironment Involvement in t-MN: Focus on Mesenchymal Stem Cells]]></title>
        <id>pubmed:37705521</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705521/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Therapy-related myeloid neoplasms (t-MN) are a late complication of cytotoxic therapy (CT) used in the treatment of both malignant and non-malignant diseases. Historically, t-MN has been considered to be a direct consequence of DNA damage induced in normal hematopoietic stem or progenitor cells (HSPC) by CT. However, we now know that treatment-induced mutations in HSC are not the only players involved in t-MN development, but additional factors may contribute to the onset of t-MN. One of the...]]></summary>
        <author>
            <name>Giulia Falconi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD]]></title>
        <id>pubmed:37705244</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37705244/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-14T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Stem cell gene therapy using the MFGS-gp91^(phox) retroviral vector was performed on a 27-year-old patient with X-linked chronic granulomatous disease (X-CGD) in 2014. The patient's refractory infections were resolved, whereas the oxidase-positive neutrophils disappeared within 6 months. Thirty-two months after gene therapy, the patient developed a myelodysplastic syndrome (MDS), and vector integration into the MECOM locus was identified in blast cells. The vector integration into MECOM was...]]></summary>
        <author>
            <name>Toru Uchiyama</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[cloneRate: fast estimation of single-cell clonal dynamics using coalescent theory]]></title>
        <id>pubmed:37699006</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37699006/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-12T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[MOTIVATION: While evolutionary approaches to medicine show promise, measuring evolution itself is difficult due to experimental constraints and the dynamic nature of body systems. In cancer evolution, continuous observation of clonal architecture is impossible, and longitudinal samples from multiple timepoints are rare. Increasingly available DNA sequencing datasets at single-cell resolution enable the reconstruction of past evolution using mutational history, allowing for a better understanding...]]></summary>
        <author>
            <name>Brian Johnson</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Fully accessible fitness landscape of oncogene-negative lung adenocarcinoma]]></title>
        <id>pubmed:37695905</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37695905/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-11T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Cancer genomes are almost invariably complex with genomic alterations cooperating during each step of carcinogenesis. In cancers that lack a single dominant oncogene mutation, cooperation between the inactivation of multiple tumor suppressor genes can drive tumor initiation and growth. Here, we shed light on how the sequential acquisition of genomic alterations generates oncogene-negative lung tumors. We couple tumor barcoding with combinatorial and multiplexed somatic genome editing to...]]></summary>
        <author>
            <name>Maryam Yousefi</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231004205006&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231003205044&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[A Leukemic Target with a Thousand Faces: The Mitochondria]]></title>
        <id>pubmed:37685874</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37685874/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[In the era of personalized medicine greatly improved by molecular diagnosis and tailor-made therapies, the survival rate of acute myeloid leukemia (AML) at 5 years remains unfortunately low. Indeed, the high heterogeneity of AML clones with distinct metabolic and molecular profiles allows them to survive the chemotherapy-induced changes, thus leading to resistance, clonal evolution, and relapse. Moreover, leukemic stem cells (LSCs), the quiescent reservoir of residual disease, can persist for a...]]></summary>
        <author>
            <name>Beatrice Maffeo</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Challenges and Prospects of Patient-Derived Xenografts for Cancer Research]]></title>
        <id>pubmed:37686627</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37686627/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-09T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[We discuss the importance of the in vivo models in elucidating cancer biology, focusing on the patient-derived xenograft (PDX) models, which are classic and standard functional in vivo platforms for preclinical evaluation. We provide an overview of the most representative models, including cell-derived xenografts (CDX), tumor and metastatic cell-derived xenografts, and PDX models utilizing humanized mice (HM). The orthotopic models, which could reproduce the cancer environment and its...]]></summary>
        <author>
            <name>Jiankang Jin</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230925205009&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230920204905&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230917204935&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230912205016&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Shared and distinct genetic etiologies for different types of clonal hematopoiesis]]></title>
        <id>pubmed:37684235</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684235/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Clonal hematopoiesis (CH)-age-related expansion of mutated hematopoietic clones-can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data in up to 482,378 UK Biobank participants to demonstrate shared genetic architecture across CH types. Our...]]></summary>
        <author>
            <name>Derek W Brown</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection Fraction]]></title>
        <id>pubmed:37681311</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37681311/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1TSNW3JJ2DCkNHmqtItKm189ayyfigsz0lfhc8yQ7h2yfXzYrl&amp;fc=20220608003622&amp;ff=20230908204701&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[CONCLUSIONS: CH is associated with worse heart function and prognosis in patients with HFpEF, and a murine experimental model of Tet2-mediated CH displays greater features of HFpEF.]]></summary>
        <author>
            <name>Jesse Cochran</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231002205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20231001205031&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230930205630&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230929204823&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230928204948&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230927204941&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230926205017&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230925205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230924205014&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230923205208&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230922204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230921204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230920204904&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230919204929&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230918204942&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230917204936&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230916205201&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230915204741&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230914204950&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230913204840&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230912205015&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230911204717&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230910204912&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[Potential value of high-throughput single-cell DNA sequencing of Juvenile myelomonocytic leukemia: report of two cases]]></title>
        <id>pubmed:37684264</id>
        <link href="https://pubmed.ncbi.nlm.nih.gov/37684264/?utm_source=axios&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1HuCGFZSJIJipW3YKC8lKs0LOntnvC4VTlDPv37z3kpJCsGYKs&amp;fc=20220608010801&amp;ff=20230909205145&amp;v=2.17.9.post6+86293ac"/>
        <updated>2023-09-08T10:00:00.000Z</updated>
        <summary type="html"><![CDATA[Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative disease of early childhood that develops due to mutations in the genes of the RAS-signaling pathway. Next-generation high throughput sequencing (NGS) enables identification of various secondary molecular genetic events that can facilitate JMML progression and transformation into secondary acute myeloid leukemia (sAML). The methods of single-cell DNA sequencing (scDNA-seq) enable overcoming limitations of bulk NGS and exploring...]]></summary>
        <author>
            <name>E V Volchkov</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nodal interferon exposure drives tumour-specific tolerance]]></title>
        <id>72a3a11d39c217b1a80cbb551444e6f6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1533878403463405569"/>
        <updated>2022-06-06T18:28:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nodal interferon exposure drives tumour-specific tolerance https://t.co/FT4NeBcFTg pic.twitter.com/NRHkVDUsOr
 NatureReviewsCancer (@NatureRevCancer) June 6, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VIBConferences: #Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.Registration Deadline: Thursday 2 June. Read more]]></title>
        <id>bb6bc242bcbc356c4a38db850e74d812</id>
        <link href="https://twitter.com/VIBConferences/status/1531132720952266752"/>
        <updated>2022-05-30T04:37:42.000Z</updated>
        <summary type="html"><![CDATA[#Cancer #immunotherapy has become a crucial pillar of anticancer therapy. 19 leading researchers at #ImmunoOnco22 will give new insights into the immune response to tumors and tackle unresolved questions.
Registration Deadline: Thursday 2 June. Read more https://t.co/cc0HC5cj6W pic.twitter.com/u8LFuzBbsV
 VIB Conferences (@VIBConferences) May 30, 2022]]></summary>
        <author>
            <name>@VIBConferences</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy]]></title>
        <id>ed6c996dc1a718afb523de6229a53131</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530198403686072320"/>
        <updated>2022-05-27T14:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Nonsense-mediated RNA decay: an emerging modulator of malignancy https://t.co/wjuHplkpof pic.twitter.com/1SoKYhRsPO
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content ]]></title>
        <id>d15a3a4b24853812d7fa21fd56de5815</id>
        <link href="https://twitter.com/NatureRevCancer/status/1530174481313972224"/>
        <updated>2022-05-27T13:10:00.000Z</updated>
        <summary type="html"><![CDATA[Our June issue, out NOW! With articles on #therapyresistance, #senescence & targeting CDK4 & CDK6 in #cancer! Plus, a Comment on cancer mRNA vaccines as well as the launch of our new Tools of the Trade articles #NRCToT. So much content 
 https://t.co/Fo6XRWV3OZ@natrescancer pic.twitter.com/rbxRPqLV6g
 NatureReviewsCancer (@NatureRevCancer) May 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@UlrikeHarjes: This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer:  do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest]]></title>
        <id>fe13755a2693ea65459e5e21df097d2a</id>
        <link href="https://twitter.com/UlrikeHarjes/status/1529747629936193537"/>
        <updated>2022-05-26T08:53:50.000Z</updated>
        <summary type="html"><![CDATA[This Review by @MarcusDGon @cantleylab is part of the @NatureRevCancer series on #Diet & #SystemicMetabolism in cancer: https://t.co/p3Y2cdNhco
I do love this topic in general plus I am handling research at @NatureMedicine now.. get in touch if you have something of interest https://t.co/qWH2dTv8j9
 Ulrike Harjes (@UlrikeHarjes) May 26, 2022]]></summary>
        <author>
            <name>@UlrikeHarjes</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Developing dietary interventions as therapy for cancer]]></title>
        <id>9ba5279424b31b0122a4ae20c18e6d03</id>
        <link href="https://twitter.com/NatureRevCancer/status/1529516411059437568"/>
        <updated>2022-05-25T17:35:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Developing dietary interventions as therapy for cancer https://t.co/ijuqctk1wJ pic.twitter.com/KHPpMKnCFa
 NatureReviewsCancer (@NatureRevCancer) May 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Digging for treasures in the tumour interactome]]></title>
        <id>611d40f2e6ea2796b028bebda41a86dd</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526928478490095616"/>
        <updated>2022-05-18T14:11:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Digging for treasures in the tumour interactome https://t.co/NhHYAwUgLE
 NatureReviewsCancer (@NatureRevCancer) May 18, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here]]></title>
        <id>9590a971b00448cd312078183965b21d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1526560254091313156"/>
        <updated>2022-05-17T13:48:21.000Z</updated>
        <summary type="html"><![CDATA[As part of our overall commitment to diversity, equity and inclusion at Springer Nature, wed like to better understand what DEI means within the global research community. Take the survey here https://t.co/03yLiUxFTq
 NatureReviewsCancer (@NatureRevCancer) May 17, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial ]]></title>
        <id>aa38ff4245b93e964773f191844ddc7a</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524772831904509953"/>
        <updated>2022-05-12T15:25:46.000Z</updated>
        <summary type="html"><![CDATA[Newsflash! We have a new article type in the journal - Tools of the Trade #NRCToT   where we hope to enable more #ECRs to interact with the editorial team & have a bigger voice in our content. For more info, check out the Editorial  https://t.co/VbyoUJmTRJ
 NatureReviewsCancer (@NatureRevCancer) May 12, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tools for the next generation]]></title>
        <id>65aca76b9f794aaa668d84ad32dca4a0</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524068259712036864"/>
        <updated>2022-05-10T16:46:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tools for the next generation https://t.co/lEzTPFYDf5
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon]]></title>
        <id>afa9b6784b4ccc7c05ed4efd26ddfb2d</id>
        <link href="https://twitter.com/NatureRevCancer/status/1524022709386190856"/>
        <updated>2022-05-10T13:45:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Hunting down rare drug-tolerant cycling cells with Watermelon https://t.co/XXT0c9SAYX
 NatureReviewsCancer (@NatureRevCancer) May 10, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@VarunVenkatara2: Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter]]></title>
        <id>43e2d5ccebc9030f737d656f47ac9d98</id>
        <link href="https://twitter.com/VarunVenkatara2/status/1520050291986604033"/>
        <updated>2022-04-29T14:40:05.000Z</updated>
        <summary type="html"><![CDATA[Very happy that our latest Perspective is now online @NatureRevCancer ! We discuss implications of malignant, multicellular networks and potential therapeutic strategies how to disconnect them. Thanks to everyone involved ! #CancerNeuroscience #TumorMicrotubes #neurotwitter https://t.co/S55cKTGNFd
 Varun Venkataramani (@VarunVenkatara2) April 29, 2022]]></summary>
        <author>
            <name>@VarunVenkatara2</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! An inhospitable site]]></title>
        <id>9f6b8644378881f4c2e6b6833c93fc2f</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020349068316673"/>
        <updated>2022-04-29T12:41:06.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! An inhospitable site https://t.co/0dvqIKCWxh pic.twitter.com/PtY8J9Fz7r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Disconnecting multicellular networks in brain tumours]]></title>
        <id>f6d91efcd60dae769e2722585bdfa8df</id>
        <link href="https://twitter.com/NatureRevCancer/status/1520020340201598978"/>
        <updated>2022-04-29T12:41:04.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Disconnecting multicellular networks in brain tumours https://t.co/LJrzy8bRma pic.twitter.com/CO7BnooP0r
 NatureReviewsCancer (@NatureRevCancer) April 29, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.]]></title>
        <id>76e3b436bc8e43ad21366a80c120e395</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519678964364623872"/>
        <updated>2022-04-28T14:04:34.000Z</updated>
        <summary type="html"><![CDATA[Our May issue, out NOW! With Reviews on #CRISPR in cancer biology & #therapy, ROS in tumour development & progression, and cancer #proteogenomics, and Comments on esophageal cancer research in Eastern Africa and on Critical Race Theory.
 https://t.co/vQwHFJhpwv@natrescancer pic.twitter.com/6kYgjRYhdT
 NatureReviewsCancer (@NatureRevCancer) April 28, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@tmurraystewart: Our latest publication on #polyamines is online!@HopkinsMedicine]]></title>
        <id>fdf224ea293cdf039086d16e5699a59a</id>
        <link href="https://twitter.com/tmurraystewart/status/1519413460978704384"/>
        <updated>2022-04-27T20:29:33.000Z</updated>
        <summary type="html"><![CDATA[Our latest publication on #polyamines is online!@HopkinsMedicine https://t.co/ehRGgN1w9R
 Tracy Murray Stewart (@tmurraystewart) April 27, 2022]]></summary>
        <author>
            <name>@tmurraystewart</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity]]></title>
        <id>4f43226ec4dc8e531ff6e64a9c5ab8e6</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519381375874265088"/>
        <updated>2022-04-27T18:22:03.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Polyamines in cancer: integrating organismal metabolism and antitumour immunity https://t.co/YCJX1hRQLO pic.twitter.com/zRUCRNXyxH
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.]]></title>
        <id>a44ed79b9f76aad377b9272fb392f553</id>
        <link href="https://twitter.com/NatureRevCancer/status/1519317944995569664"/>
        <updated>2022-04-27T14:10:00.000Z</updated>
        <summary type="html"><![CDATA[NEW #ResearchHighlight! Lv, Liu, Mo & co demonstrate that in pancreatic #PDAC cells, gasdermin E transports YBX1 to the nucleus, which promotes mucin expression, thereby providing tumour cells with a barrier against digestive enzymes.
 https://t.co/JTUhX0DHQ1@natrescancer pic.twitter.com/2PdCmsDu2p
 NatureReviewsCancer (@NatureRevCancer) April 27, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino  @natrescancer @Columbia]]></title>
        <id>06ff7641d8f5fcc0dff91f835ac3bbc1</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518967636561956865"/>
        <updated>2022-04-26T14:58:00.000Z</updated>
        <summary type="html"><![CDATA[In the April issue of @NatureRevCancer | Comment, Reimagining cancer research with art, by @CancerSciArtist, Stefani Shoreibah & @tdanino
 https://t.co/GeTVCMJQsp @natrescancer
 @Columbia pic.twitter.com/ZXW6A0Fe0c
 NatureReviewsCancer (@NatureRevCancer) April 26, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
    <entry>
        <title type="html"><![CDATA[@NatureRevCancer: NEW content online! Tracking dormant disseminated tumour cells]]></title>
        <id>96b2ddff4eb269cf343213c6a1b1ce95</id>
        <link href="https://twitter.com/NatureRevCancer/status/1518563607440621569"/>
        <updated>2022-04-25T12:12:32.000Z</updated>
        <summary type="html"><![CDATA[NEW content online! Tracking dormant disseminated tumour cells https://t.co/kSXyWAvCxF
 NatureReviewsCancer (@NatureRevCancer) April 25, 2022]]></summary>
        <author>
            <name>@NatureRevCancer</name>
        </author>
    </entry>
</feed>